TNFRSF12A and breast cancer: The observation that TweakR is expressed in multiple subtypes of breast cancer and that enavatuzumab exhibits potent in vitro and in vivo activity, both as monotherapy and in combination with other agents, provides the rationale for further evaluation of enavatuzumab for the treatment of breast cancer.